Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2006

View Archived Issues

Clinical snapshots: cancer-related anemia, immune thrombocytopenic purpura

First trial of ProGenic pimecrolimus drug-eluting coronary stent opens enrollment

PsychoGenics and Lilly establish drug discovery and development agreement

Medivir and Presidio sign license agreements for alovudine and MIV-410

MediGene acquires E.U. rights to Oracea, establishes E.U. sales force

Indian approval for phase III evaluation of LLL-2011 for migraine prophylaxis

Regulatory pathway toward phase III and U.S. orphan drug designation for Ampydin (IR)

Rabirix rabies vaccine launched in India

Second phase III study for intravenous methylnaltrexone in POI

Outlicensing activities continue for CYT002-NicQb in nicotine addiction

MorphoSys and Pfizer expand therapeutic antibody collaboration

ADX-10059 begins proof-of-concept study in moderately severe dental anxiety

Bevirimat shows antiviral activity, but plasma concentrations lower than expected

Promising in vivo results with 17beta-HSD1 inhibitor from Sterix

Preliminary topline phase III results for PolyHeme

Androxal shows noninferiority to Androgel in phase III interim analysis

Targeting protein tyrosine phosphatase 1B shows promise for the treatment of heart failure

U.S. orphan drug designation for smallpox drug SIGA-246

Ista files IND for bepotastine eye drops for allergic conjunctivitis

Second approvable letter for Vyvanse

Approvable letter for Combigan

Exforge approved for hypertension

NDA submission for sevelamer carbonate for patients on dialysis

Japanese approval sought for Fosrenol in hyperphosphatemia

Recent patents disclose novel antiinfective agents

Recent Pfizer and Novartis patents impart new therapeutic agents for hypertension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...